Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA)

Web site

Administrative institutions

Université de Lille
CHU Lille

Presentation

Les axes de recherche développés au sein du Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) sont orientés vers les médicaments injectables, les dispositifs médicaux de perfusion et la modélisation biopharmaceutique et pharmacocinétique. L'unité est une équipe d'accueil (EA 7365) sous la tutelle de l'Université de Lille et du CHU de Lille.

Research teams

Innovation/évaluation des dispositifs médicaux de perfusion
Innovation/évaluation des médicaments injectables
Modélisation biopharmaceutique et pharmacocinétique

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Web site

Administrative institutions

Presentation

Research teams

Recent Submissions

Translation of the REMEDI[e]S (Review of potentially inappropriate MEDIcation pr[e]scribing in Seniors) explicit criteria into seminatural language for use in prescription support systems: A multidisciplinary consensus.

Evaluation of the economic impact and the patient pathway in the treatment of chronic total occlusion

Potential Sampling Errors in Stability Studies Due to Dead Volume in Closed System Transfer Devices

Prévention de la rechute des leucémies aiguës et syndromes myélodysplasiques en post-allogreffe : stratégies prophylactique et préemptive (SFGM-TC)

Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final Analysis

Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups)

ZUMA-23 : a global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma

Radiomics reflecting both tumor and host features improves outcome prediction in follicular lymphoma

Romidepsin plus chop versus chop in patients with previously untreated peripheral T-Cell lymphoma : final analysis of the ro-chop trial

A low lymphocyte-to-monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Web site

Administrative institutions

Presentation

Research teams

Recent Submissions

Translation of the REMEDI[e]S (Review of potentially inappropriate MEDIcation pr[e]scribing in Seniors) explicit criteria into seminatural language for use in prescription support systems: A multidisciplinary consensus. ﻿

Evaluation of the economic impact and the patient pathway in the treatment of chronic total occlusion ﻿

Potential Sampling Errors in Stability Studies Due to Dead Volume in Closed System Transfer Devices ﻿

Prévention de la rechute des leucémies aiguës et syndromes myélodysplasiques en post-allogreffe : stratégies prophylactique et préemptive (SFGM-TC) ﻿

Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final Analysis ﻿

Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups) ﻿

ZUMA-23 : a global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma ﻿

Radiomics reflecting both tumor and host features improves outcome prediction in follicular lymphoma ﻿

Romidepsin plus chop versus chop in patients with previously untreated peripheral T-Cell lymphoma : final analysis of the ro-chop trial ﻿

A low lymphocyte-to-monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial ﻿

Translation of the REMEDI[e]S (Review of potentially inappropriate MEDIcation pr[e]scribing in Seniors) explicit criteria into seminatural language for use in prescription support systems: A multidisciplinary consensus.

Evaluation of the economic impact and the patient pathway in the treatment of chronic total occlusion

Potential Sampling Errors in Stability Studies Due to Dead Volume in Closed System Transfer Devices

Prévention de la rechute des leucémies aiguës et syndromes myélodysplasiques en post-allogreffe : stratégies prophylactique et préemptive (SFGM-TC)

Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final Analysis

Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups)

ZUMA-23 : a global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma

Radiomics reflecting both tumor and host features improves outcome prediction in follicular lymphoma

Romidepsin plus chop versus chop in patients with previously untreated peripheral T-Cell lymphoma : final analysis of the ro-chop trial

A low lymphocyte-to-monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial